[go: up one dir, main page]

NO20052177L - Anvendelse av galantamin og dets derivater for fremstilling av legemidler - Google Patents

Anvendelse av galantamin og dets derivater for fremstilling av legemidler

Info

Publication number
NO20052177L
NO20052177L NO20052177A NO20052177A NO20052177L NO 20052177 L NO20052177 L NO 20052177L NO 20052177 A NO20052177 A NO 20052177A NO 20052177 A NO20052177 A NO 20052177A NO 20052177 L NO20052177 L NO 20052177L
Authority
NO
Norway
Prior art keywords
galantamine
manufacture
derivatives
drugs
post
Prior art date
Application number
NO20052177A
Other languages
English (en)
Other versions
NO20052177D0 (no
Inventor
Eberhard Pirich
Werner Frantsits
Laszlo Czollner
Angelika Bodenteich
Original Assignee
Sanochemia Pharmazeutika Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Ag filed Critical Sanochemia Pharmazeutika Ag
Publication of NO20052177D0 publication Critical patent/NO20052177D0/no
Publication of NO20052177L publication Critical patent/NO20052177L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår anvendelse av galantamin og kolinergisk aktive derivater derav for fremstilling av medikamenter for preventiv behandling av postoperativ delirium og/eller undersyndron post-operativ delirium. Galantamin, galantaminderivatet (4aS, 6R, 8aS)-6-hydroksy-3-metoksy- 11 -metyl-4a,5,9,10-tetrahydro-6H-benzofuro[3a, 3, 2-ef] [2]benzazepiniumbromid og analoge salter, hydrater og solvater er fordelaktig egnet for anvendelse ifølge oppfinnelsen.
NO20052177A 2003-09-29 2005-05-03 Anvendelse av galantamin og dets derivater for fremstilling av legemidler NO20052177L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT15382003 2003-09-29
PCT/AT2004/000251 WO2005030332A2 (de) 2003-09-29 2004-07-12 Verwendung von galanthamin und seinen derivaten zum herstellen von arzneimitteln

Publications (2)

Publication Number Publication Date
NO20052177D0 NO20052177D0 (no) 2005-05-03
NO20052177L true NO20052177L (no) 2005-06-24

Family

ID=34382391

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052177A NO20052177L (no) 2003-09-29 2005-05-03 Anvendelse av galantamin og dets derivater for fremstilling av legemidler

Country Status (7)

Country Link
US (1) US20060111341A1 (no)
EP (1) EP1667769A2 (no)
CN (1) CN1859949A (no)
CA (1) CA2506282A1 (no)
MX (1) MXPA05005570A (no)
NO (1) NO20052177L (no)
WO (1) WO2005030332A2 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
CN104860955B (zh) * 2015-04-22 2017-07-14 华东理工大学 加兰他敏类似物及其用途
WO2017189834A1 (en) * 2016-04-29 2017-11-02 New Mexico Tech Research Foundation Methods for treatment of resistant cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
US6407229B1 (en) * 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
SI0787115T1 (en) * 1994-10-21 2000-04-30 Sanochemia Pharmazeutika Ag PROCESS FOR PRODUCING DERIVATIVES OF 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO(3a,3,2-ef)(2)BENZAZEPINE
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
EP1133290B1 (de) * 1998-11-27 2003-03-12 Sanochemia Pharmazeutika Aktiengesellschaft Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien

Also Published As

Publication number Publication date
CA2506282A1 (en) 2005-04-07
CN1859949A (zh) 2006-11-08
NO20052177D0 (no) 2005-05-03
WO2005030332A3 (de) 2005-06-02
US20060111341A1 (en) 2006-05-25
WO2005030332A2 (de) 2005-04-07
MXPA05005570A (es) 2005-10-18
EP1667769A2 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
MXPA03012013A (es) Derivados de 1-oxa-2,8-diaza-spiro[4,5]dec-2-eno sustituidos como medicamento para el tratamiento de dolor.
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
MX2007004781A (es) Derivados de 3-arilamino piridina.
GEP20063831B (en) Substituted bicyclic derivatives for treatment of abnormal cell growth
AU2002246728A1 (en) Carboline derivatives
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
AU2002249890A1 (en) Carboline derivatives
TW200640913A (en) 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
WO2002010152A3 (de) Neue indolderivate und deren verwendung als arzneimittel
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
WO2005105753A8 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
DE50310080D1 (de) 3-SUBSTITUIERTE 3,4-DIHYDRO-THIENOi2,3-D PYRIMIDIN-4-ONE-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
NO20052177L (no) Anvendelse av galantamin og dets derivater for fremstilling av legemidler
NO20062599L (no) Fremgangsmate for syntese av perindopril og farmasoytisk akseptable salter derav
MY136938A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
MY139159A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
WO2003089449A3 (fr) Composes aminoalkylsteroles avec activite anti-tumeur et neuroprotective
MY139348A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application